Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2857–2880 of 21,235 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Immunity Disorders Clear all

Conditions: Atopic Dermatitis
Interventions: Fluzone® Intradermal (Sanofi Pasteur Inc.); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Breast Cancer, Leukemia, Lymphoma
Interventions: HeartPhone app, Acetylcholine, Sodium Nitroprusside, L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester; Behavioral · Drug
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
Interventions: Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel, Mosunetuzumab, Patient Observation, Polatuzumab Vedotin, Positron Emission Tomography, Tisagenlecleucel; Biological · Procedure · Drug + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 95
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 74 more

Conditions: HIV Antibody Positivity
Interventions: Mobile health app; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 29 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Multiple Sclerosis
Interventions: 800g Challenge; Behavioral
Lead sponsor: University of North Texas, Denton, TX; Other
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Denton, Texas

Conditions: Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Refractory Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Hodgkin Lymphoma, Refractory Childhood Malignant Germ Cell Neoplasm, Recurrent Childhood Brain Tumor, Recurrent Childhood Brainstem Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Ependymoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Gliosarcoma, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions: Not listed
Lead sponsor: Florida International University; Other
Eligibility: 1 Day to 21 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis
Interventions: Etanercept / Autoinjector A; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 13
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 10 more

Conditions: T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Interventions: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Mercaptopurine, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Venetoclax, Vincristine Sulfate; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Asthma
Interventions: ipratropium; Drug
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Membranous Nephropathy, Nephrotic Syndrome
Interventions: Belimumab, Placebo for Belimumab, Rituximab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 20
States / cities: Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 17 more

Conditions: Hepatic Insufficiency
Interventions: Alisporivir; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis
Interventions: No Intervention; Other
Lead sponsor: ProgenaBiome; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Ventura, California

Conditions: Stroke, Traumatic Brain Injury, Multiple Sclerosis, Spasticity, Healthy Controls
Interventions: Not listed
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Healthy, Neurodegenerative Disease
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 200,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections, Pregnancy
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 6 Months
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 8
States / cities: La Jolla, California • Long Beach, California • Los Angeles, California + 1 more

Conditions: HIV Infections
Interventions: Atazanvir/ritonavir + efavirenz; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 15
States / cities: San Francisco, California • Washington D.C., District of Columbia • Atlantis, Florida + 12 more

Conditions: Atopic Dermatitis
Interventions: KT-621, Placebo; Drug · Other
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 12 more

Conditions: Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor B-cell Lymphoblastic Leukemia-Lymphoma
Interventions: SGN-CD19A; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 6
States / cities: Birmingham, Alabama • Duarte, California • Stanford, California + 3 more

Conditions: Metastatic Cancer, Locally Advanced Cancer, Thoracic Cancer, Gynecologic Cancer, Genitourinary Cancer, Lymphoma
Interventions: Weekly 45 minute Sessions; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Solid Tumors, Lymphoma
Interventions: CDDO; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atopic Dermatitis (AD)
Interventions: TMT Lotion, Placebo Lotion; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: San Diego, California • Denver, Colorado

Conditions: Atopic Dermatitis, Pruritus
Interventions: Levocetirizine dihydrochloride (Xyzal), placebo; Drug
Lead sponsor: Derm Research, PLLC; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate, methylprednisolone, total-body irradiation; Biological · Drug · Radiation
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: Up to 50 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 4
States / cities: Nashville, Tennessee

Conditions: Multiple Myeloma, Non-Hodgkins Lymphoma
Interventions: Plerixafor; Drug
Lead sponsor: Shi, Patricia, M.D.; Individual
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot

HeartPhone Cancer Survivors Trial 2019

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Feasibility of Positive Links for Youth Care Engagement Intervention

Examining the Impact of an Online, Non-restrictive Diet Among Persons With Multiple Sclerosis

Ex Vivo Drug Sensitivity Testing and Mutation Profiling

Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation

Belimumab With Rituximab for Primary Membranous Nephropathy

Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects

A Pilot Study to Explore the Role of Gut Flora in Rheumatoid Arthritis

Validation of an Obstacle Course Used in Patients With Muscle Tightness

Brain Health Registry: An Online Registry to Identify and Assess Subjects for Brain Research

Setting up a Blood Bank for Gene Therapy in HIV-Infected Infants

A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

A Safety Study of SGN-CD19A for B-Cell Lymphoma

An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer

CDDO to Treat Solid Tumors and Lymphomas

Targeted Microbiome Transplant in Atopic Dermatitis

Management of Pruritus With Xyzal in Atopic Dermatitis

Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil

Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection